Larimar Therapeutics (LRMR) Stock
Clinical-stage biotech firm developing new medicines through trials. Here's the price, business snapshot, and what's worth knowing about Larimar Therapeutics in October 2026.
Larimar Therapeutics Inc (LRMR) is a clinical-stage biotechnology company with a developing pipeline of therapeutic candidates. With a market capitalisation of roughly $367 million, Larimar is focused on advancing programmes through clinical trials, seeking to demonstrate safety and efficacy to attract partner interest or commercial opportunities. For investors, key considerations are trial readouts, regulatory milestones, cash runway, and potential dilution from future financing — common themes for small biotech firms. Clinical-stage companies can offer significant upside if trials succeed, but they also carry higher technical and regulatory risk and often lack steady revenues. Larimar’s progress will be driven by clinical data, partnerships and strategic execution. This summary is educational and not investment advice; investors should review company filings, trial results, and consult a financial adviser to assess suitability for their individual circumstances.
Larimar Therapeutics (LRMR) Stock Forecast
Analyst price target, next 12 months
$17.67
+561.7% vs today's $2.67
Price range over the last 12 months
Close to its 12-month low
Analysts covering Larimar Therapeutics have a consensus 12-month target of $17.67, above the current price of $2.67.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Larimar's stock with a target price of $17.67, indicating significant potential for profit.
Financial Health
Larimar Therapeutics is showing promising cash flow and book value per share, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory steps can materially affect value; positive data may drive interest, though outcomes are uncertain and volatile.
Development Focus
Progress depends on scientific results and execution; strong data can open partnership or commercial options, but setbacks are possible.
Monitor Funding Needs
Small biotechs often require further capital to fund trials, which can dilute shareholders; check filings for cash runway and financing plans.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
